title: Innovative personalized medicine in gastric cancer: time to move forward.
abstract: Globally, gastric cancer (GC) is the second leading cancer cause of death. To date, only one targeted therapy trial generated positive survival outcomes in a selected population among many targeted therapy trials. This trial showed the addition of trastuzumab to fluoropyrimidine/platinum chemotherapy as first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive GC that resulted in an overall survival (OS) benefit. The increasing use of next generation sequencing approach to genomically profile GC patients allows the identification of many more GC patients who could benefit from specific targeted agents. Here we provide a comprehensive review of targeted therapy trials in GC and discuss future potential actionable driver mutations in GC.
authors.affiliation: Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center,Sungkyunkwan University School of Medicine, Seoul, South Korea.
authors.forename: J
authors.initials: J
authors.lastname: Lee
authors.forename: K-M
authors.initials: KM
authors.lastname: Kim
authors.forename: W K
authors.initials: WK
authors.lastname: Kang
authors.forename: S-H I
authors.initials: SH
authors.lastname: Ou
mesh_terms: D002986:Clinical Trials as Topic; D004268:DNA-Binding Proteins; D066246:ErbB Receptors / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D009687:Nuclear Proteins / Q000235:genetics / Q000378:metabolism; D057285:Precision Medicine / Q000379:methods* / Q000639:trends; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000378:metabolism; D019859:Proto-Oncogene Proteins c-met / Q000235:genetics* / Q000378:metabolism; D016283:Proto-Oncogene Proteins p21(ras); D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics* / Q000378:metabolism; D051497:Receptor, Fibroblast Growth Factor, Type 2 / Q000235:genetics / Q000378:metabolism; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D018631:ras Proteins / Q000235:genetics / Q000378:metabolism
chemical_list: D004268:DNA-Binding Proteins; D066246:ErbB Receptors; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D019859:Proto-Oncogene Proteins c-met; D016283:Proto-Oncogene Proteins p21(ras); D018719:Erb-b2 Receptor Tyrosine Kinases; D051497:Receptor, Fibroblast Growth Factor, Type 2; D014157:Transcription Factors; D042461:Vascular Endothelial Growth Factor A; D018631:ras Proteins; C112476:ARID1A protein, human; C117307:KRAS protein, human; C512478:EGFR protein, human; C508053:ERBB2 protein, human; C496353:FGFR2 protein, human; C491743:MET protein, human
keywords: actionable mutations; chemotherapy; gastric cancer; molecularly targeted agents; personalized medicine